CA2842518C - Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones - Google Patents

Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones Download PDF

Info

Publication number
CA2842518C
CA2842518C CA2842518A CA2842518A CA2842518C CA 2842518 C CA2842518 C CA 2842518C CA 2842518 A CA2842518 A CA 2842518A CA 2842518 A CA2842518 A CA 2842518A CA 2842518 C CA2842518 C CA 2842518C
Authority
CA
Canada
Prior art keywords
compound
salt
mmol
formula
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2842518A
Other languages
English (en)
French (fr)
Other versions
CA2842518A1 (en
Inventor
Jerome Emile Georges Guillemont
David Francis Alain Lancois
Magali Madeleine Simone Motte
Anil Koul
Wendy Mia Albert Balemans
Eric Pierre Alexandre Arnoult
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46650549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2842518(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of CA2842518A1 publication Critical patent/CA2842518A1/en
Application granted granted Critical
Publication of CA2842518C publication Critical patent/CA2842518C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA2842518A 2011-08-10 2012-08-10 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones Active CA2842518C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11177119.2 2011-08-10
EP11177119 2011-08-10
PCT/EP2012/065733 WO2013021054A1 (en) 2011-08-10 2012-08-10 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones

Publications (2)

Publication Number Publication Date
CA2842518A1 CA2842518A1 (en) 2013-02-14
CA2842518C true CA2842518C (en) 2019-07-23

Family

ID=46650549

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2842518A Active CA2842518C (en) 2011-08-10 2012-08-10 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones

Country Status (24)

Country Link
US (7) US8906923B2 (enExample)
EP (1) EP2742045B1 (enExample)
JP (2) JP5921687B2 (enExample)
KR (1) KR101996862B1 (enExample)
CN (2) CN105461684B (enExample)
AR (1) AR087508A1 (enExample)
AU (1) AU2012293621B2 (enExample)
BR (1) BR112014003063B1 (enExample)
CA (1) CA2842518C (enExample)
CL (1) CL2014000289A1 (enExample)
DK (1) DK2742045T3 (enExample)
EA (1) EA201490438A1 (enExample)
ES (1) ES2721658T3 (enExample)
HU (1) HUE042978T2 (enExample)
IL (1) IL230549A (enExample)
JO (1) JO3611B1 (enExample)
MX (1) MX348128B (enExample)
PE (1) PE20141410A1 (enExample)
PH (1) PH12014500317A1 (enExample)
TR (1) TR201905537T4 (enExample)
TW (1) TWI568731B (enExample)
UA (1) UA111210C2 (enExample)
UY (1) UY34253A (enExample)
WO (1) WO2013021054A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013021052A1 (en) 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
WO2014023814A1 (en) * 2012-08-10 2014-02-13 Janssen R&D Ireland New antibacterial compounds
US9540324B2 (en) 2013-09-26 2017-01-10 Luc Therapeutics, Inc. Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
US11691967B2 (en) 2018-03-12 2023-07-04 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
LT3880675T (lt) 2018-11-12 2024-12-27 Debiopharm International Sa Antibiotikų junginiai, jų gamybos būdas, farmacinės kompozicijos, kurių sudėtyje jie yra, ir jų panaudojimas
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
MX2023010941A (es) * 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215123A (en) * 1979-05-07 1980-07-29 American Home Products Corporation Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
EP1225895B1 (en) 1999-10-08 2005-05-04 Affinium Pharmaceuticals, Inc. Fab i inhibitors
JP4831907B2 (ja) 1999-10-08 2011-12-07 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
ES2231275T3 (es) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
JP4387804B2 (ja) 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
US8450307B2 (en) 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US7732612B2 (en) 2004-09-09 2010-06-08 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
CA2776849A1 (en) * 2009-11-18 2011-05-26 Fab Pharma S.A.S. Novel heterocyclic acrylamides and their use as pharmaceuticals
US8766017B2 (en) 2011-07-29 2014-07-01 Eastman Chemical Company Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid
CA2843643A1 (en) 2011-07-29 2013-02-07 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hiv
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
CN104039782A (zh) 2011-08-10 2014-09-10 爱尔兰詹森研发公司 抗菌的高哌啶基取代的3,4二氢1h[1,8]萘啶酮类
WO2013021052A1 (en) 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones

Also Published As

Publication number Publication date
MX348128B (es) 2017-05-26
HK1199243A1 (zh) 2015-06-26
UA111210C2 (uk) 2016-04-11
TWI568731B (zh) 2017-02-01
CA2842518A1 (en) 2013-02-14
US8906923B2 (en) 2014-12-09
US9884864B2 (en) 2018-02-06
US20150080413A1 (en) 2015-03-19
ES2721658T3 (es) 2019-08-02
US20160194324A1 (en) 2016-07-07
JP2016190843A (ja) 2016-11-10
AR087508A1 (es) 2014-03-26
PH12014500317A1 (en) 2014-04-14
IL230549A0 (en) 2014-03-31
US9290493B2 (en) 2016-03-22
KR101996862B1 (ko) 2019-07-05
IL230549A (en) 2017-07-31
EP2742045B1 (en) 2019-01-23
US10155759B2 (en) 2018-12-18
CL2014000289A1 (es) 2014-07-11
CN105461684B (zh) 2018-09-25
CN103874698B (zh) 2016-03-23
UY34253A (es) 2013-02-28
JO3611B1 (ar) 2020-08-27
NZ620212A (en) 2015-10-30
KR20140072034A (ko) 2014-06-12
WO2013021054A1 (en) 2013-02-14
US20190084982A1 (en) 2019-03-21
TW201313714A (zh) 2013-04-01
BR112014003063B1 (pt) 2020-11-17
AU2012293621B2 (en) 2016-07-21
HUE042978T2 (hu) 2019-07-29
US10501463B2 (en) 2019-12-10
US9617262B2 (en) 2017-04-11
TR201905537T4 (tr) 2019-05-21
JP2014531404A (ja) 2014-11-27
MX2014001600A (es) 2014-04-25
HK1223352A1 (zh) 2017-07-28
US20140171451A1 (en) 2014-06-19
EA201490438A1 (ru) 2014-06-30
US10526331B2 (en) 2020-01-07
US20170174683A1 (en) 2017-06-22
BR112014003063A2 (pt) 2017-02-21
JP5921687B2 (ja) 2016-05-24
CN105461684A (zh) 2016-04-06
US20190194194A1 (en) 2019-06-27
US20180105525A1 (en) 2018-04-19
DK2742045T3 (en) 2019-04-23
EP2742045A1 (en) 2014-06-18
CN103874698A (zh) 2014-06-18
PE20141410A1 (es) 2014-10-13
AU2012293621A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
US10526331B2 (en) Antibacterial cyclopenta[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
CA2842531C (en) Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
CA2842526C (en) Antibacterial homopiperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
CA2879623A1 (en) Fused bicyclic azole heterocycle as inhibitors of the enzyme fabi
CA2880262A1 (en) Nitrogen-based heterocycloalkyl derivatives as inhibitors of the enzyme fabi
HK1223352B (en) Antibacterial cyclopenta[c]pyrrole substituted 3,4 dihydro 1h [1,8]naphthyridinones
EA043636B1 (ru) АНТИБАКТЕРИАЛЬНЫЕ 3,4-ДИГИДРО-1Н-[1,8]НАФТИРИДИНОНЫ, ЗАМЕЩЕННЫЕ ЦИКЛОПЕНТА[с]ПИРРОЛОМ

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170809

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251014

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713